Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.

The Indian journal of medical research - 1 Oct 2010

Sazawal Sudha, Bajaj Jyoti, Chikkara Sunita, Jain Sonal, Bhargava Rahul, Mahapatra Manoranjan, Saxena Renu

Abstract excerpt

BACKGROUND & OBJECTIVES: The Janus-associated Kinase-2 mutation JAK2 V617F in chronic myeloproliferative disorders (CMPDs) has been described as a frequent genetic event in majority of patients with polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). Its frequency varies in different populations but there are no data from India. We therefore, looked for JAK2 V617F mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Electrophoresis, Agar Gel
Share to Hemoglobins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Leukocyte Count

Share to Myeloproliferative Disorders

Share to Restriction Mapping

Share to Statistics, Nonparametric

Source

Identifiers

PMID: 20966521

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.PMID 20966521Read ↗

A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.Semantic proximity Read ↗

Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.Semantic proximity Read ↗

Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience.Semantic proximity Read ↗

Frequency of Janus associated kinase 2 (V617F) mutation in patients of polycythemia vera.Semantic proximity Read ↗

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

[Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].Semantic proximity Read ↗

Myeloproliferative neoplasms and JAK2 mutations.Semantic proximity Read ↗

Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.Semantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.